Showing results (1-10 of 396) with videos related to
Sort By:
Pageof 40
Science Translational Medicine|September 27, 2019
Wrangling RNA: Antisense oligonucleotides for neurological disordersKevin Talbot, Matthew J A WoodHuman Molecular Genetics|October 5, 2017
Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscapeMatthew J A Wood, Kevin Talbot, Melissa BowermanMethods in Molecular Biology (Clifton, N.J.)|September 1, 2020
Development of LNA Gapmer Oligonucleotide-Based Therapy for ALS/FTD Caused by the C9orf72 Repeat ExpansionChaitra Sathyaprakash, Raquel Manzano, Miguel A Varela, et al.Disease Models & Mechanisms|August 4, 2017
Therapeutic strategies for spinal muscular atrophy: SMN and beyondMelissa Bowerman, Catherina G Becker, Rafael J Yáñez-Muñoz, et al.Journal of Anatomy|September 10, 2013
Amyotrophic lateral sclerosis: cell vulnerability or system vulnerability?Kevin TalbotScience Translational Medicine|April 29, 2010
Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challengeMatthew J A WoodHuman Molecular Genetics|September 22, 2006
Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative diseaseKevin Talbot, Olaf AnsorgeCurrent Opinion in Neurology|September 23, 2003
Spinal muscular atrophies reveal motor neuron vulnerability to defects in ribonucleoprotein handlingKirstie Anderson, Kevin TalbotPractical Neurology|July 30, 2022
Pathological laughter and crying in neurological disorders: recognition and treatmentEmma Husbands, Kevin TalbotBioessays : News and Reviews in Molecular, Cellular and Developmental Biology|September 21, 2011
Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriersSamira Lakhal, Matthew J A WoodPageof 40